|
System | Type | Disorder | Pubmed |
cancer | digestive | stomach |  |
RUNX3 can be relocalized in the nucleus by an SRC inhibitor, in gastric cancers, providing an additional rationale for developing SRC inhibitors as anti-cancer drugs | cancer | reproductive | breast |  |
RUNX3 can be relocalized in the nucleus by an SRC inhibitor, in breast cancers, providing an additional rationale for developing SRC inhibitors as anti-cancer drugs | immunology | inflammatory | |  |
both SRC and NOS3 inhibition may be important therapeutic targets to prevent or limit vascular inflammation |
|